Business Context and Reporting Period
Company: DaVita Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2006
Business Overview: DaVita is a leading provider of dialysis services. The reporting period reflects the full integration of the DVA Renal Healthcare acquisition (completed October 2005) and the impact of new accounting standards (FAS 123(R)) adopted in January 2006.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2006 | Nine Months Ended Sep 30, 2006 | Nine Months Ended Sep 30, 2005 |
|---|---|---|---|
| Net Operating Revenues | $1,237,041 | $3,608,045 | $1,840,603 |
| Operating Income | $217,094 | $550,921 | $306,589 |
| Net Income | $94,856 | $215,562 | $164,494 |
| Diluted EPS | $0.90 | $2.04 | $1.58 |
| Cash from Operating Activities | N/A | $329,463 | $302,210 |
| Long-Term Debt (Total) | $3,824,751 | $3,824,751 | $4,157,202 |
| Cash and Equivalents | $260,278 | $260,278 | $431,811 (Dec 31, 2005) |
Key Ratios & Data:
- Operating Margin (9M 2006): 15.3% (excluding valuation gain)
- Days Sales Outstanding (DSO): Approximately 70 days (Sep 30, 2006)
- Effective Interest Rate: 6.72% (as of Sep 30, 2006)
Material Changes vs. Prior Period
- Revenue Growth: Net operating revenues increased 96% year-over-year for the nine-month period, primarily driven by the acquisition of DVA Renal Healthcare, which contributed approximately $1.48 billion in revenue.
- Profitability: Net income increased 31% year-over-year. Operating income rose significantly, aided by a one-time valuation gain of $37.968 million related to the amendment of the Product Supply Agreement with Gambro.
- Expense Trends: Patient care costs remained stable as a percentage of revenue (69.8% for 9M 2006 vs. 67.3% for 9M 2005). General and administrative expenses increased in absolute dollars due to the DVA acquisition, integration costs, and the adoption of FAS 123(R) stock-based compensation.
- Debt Reduction: Total long-term debt decreased by approximately $332 million compared to year-end 2005 due to significant principal prepayments on Term Loan A and Term Loan B.
- Accounting Changes: Adoption of FAS 123(R) resulted in the recognition of $18.9 million in stock-based compensation expense for the nine months ended September 30, 2006.
Guidance, Outlook, and Risks
Management Guidance
- 2006 Operating Income: Revised guidance to $690 million - $700 million (excluding the $38 million valuation gain).
- 2007 Operating Income: Projected range of $680 million - $750 million.
- Capital Expenditures: Expected to spend $110-$120 million on maintenance/IT and approximately $220 million on new center development and acquisitions for the remainder of 2006.
- Cash Flow: Anticipated operating cash flow of approximately $500 million for 2006 and $400-$500 million for 2007.
Material Risks and Contingencies
- Government Investigations: The Company is cooperating with multiple subpoenas from U.S. Attorney's Offices (Missouri, New York, Pennsylvania) regarding billing practices, pharmaceutical administration (EPO), and relationships with physicians. Potential outcomes include substantial penalties or exclusion from Medicare/Medicaid.
- Regulatory Changes: Risks associated with potential reductions in Medicare/Medicaid payment rates and changes to the composite rate structure for ESRD services.
- Commercial Payor Rates: Approximately 35% of revenue comes from commercial payors; consolidation among payors may lead to downward pressure on reimbursement rates.
- Product Supply Agreement: While amended to reduce obligations, the agreement with Gambro still limits the ability to source products from alternative suppliers for a significant portion of needs.
Investor Verification Checklist
- Valuation Gain Impact: Verify the sustainability of operating income by excluding the $38 million one-time gain from the Product Supply Agreement amendment.
- DSO Trends: Monitor the Days Sales Outstanding (70 days), which increased due to temporary CMS claims processing suspensions, to ensure collection efficiency returns to normal.
- Legal Exposure: Assess the potential financial impact of ongoing federal investigations and subpoenas regarding billing and physician relationships.
- Debt Service: Confirm the Company's ability to service its debt load (approx. $3.8 billion) given the high interest expense ($206.8 million for 9M 2006) and reliance on operating cash flow.
- Commercial Mix: Track the percentage of revenue derived from commercial payors versus government programs to evaluate exposure to rate cuts.